PPCB ▼ -1.0% - Propanc Biopharma, Inc. $PPCB - Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 Propanc Biopharma's stock declined 1.0% today despite the company announcing plans to initiate a Phase 1b first-in-human study of its PRP candidate in February 2027. The timing of the clinical advancement, which remains more than a year away, may have tempered immediate investor enthusiasm for the early-stage pancreatic cancer treatment program. 09-SEP-2026 08:32 AM ET